MedTrace Logo

Effect of Doxycycline on Cardiac Remodelling in STEMI Patients

NCT03960411 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-08-06

No results posted yet for this study

Summary

Subsequent to the loss of myocardium post-myocardial infarction (MI), the affected ventricle undergoes some dynamic structural and functional changes known as remodeling. Cardiac remodeling progresses into heart failure (HF). In this revolutionized percutaneous coronary intervention (PCI) era, the incidence of post-MI HF due to cardiac remodeling remains high. Current standard therapeutic interventions, for HF, aimed solely at correcting a low cardiac output do not necessarily impede HF progression. Recently, doxycycline was found to have an additional biological effect aside from their antimicrobial actions. From several experimental studies and clinical trials, doxycycline showed MMP inhibition activities that can prevent ventricular remodeling. This study aims to evaluate the role of doxycycline in cardiac remodeling prevention post-MI. Our hypothesis is that a better heart function will be observed in STEMI patients who receive a short period of doxycycline administration post-PCI.

Conditions

  • ST Elevation Myocardial Infarction
  • Anterior Wall Myocardial Infarction
  • Heart Failure
  • Remodeling, Ventricular

Interventions

DRUG

Doxycycline 100Mg Capsule

Doxycycline capsule

DRUG

Placebo oral capsule

Capsule manufactured to mimic doxycycline 100 mg capsule

Sponsors & Collaborators

  • National Cardiovascular Center Harapan Kita Hospital Indonesia

    collaborator OTHER

  • Felix Chikita Fredy, MD

    lead OTHER

Principal Investigators

  • Bambang Widyantoro, PhD · Indonesia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-25
Primary Completion
2019-08-31
Completion
2019-11-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03960411 on ClinicalTrials.gov